Neovasc Inc. EV/Sales

EV/Sales of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Sales growth rates and interactive chart. Compares the total enterprise value of a company to its sales. It is a more accurate measure of business value, as it takes into account cash and debt on the balance sheet. A company with large cash holdings and no debt will show a significantly lower EV/S than P/S ratio.


Highlights and Quick Summary

Current EV/Sales of Neovasc Inc. is -4.17 (as of December 31, 2021)
  • EV/Sales for the quarter ending March 31, 2022 was -0.98 (a -76.44% decrease compared to previous quarter)
  • Year-over-year quarterly EV/Sales decreased by -126.41%
  • Annual EV/Sales for 2021 was -4.17 (a -143.08% decrease from previous year)
  • Annual EV/Sales for 2020 was 9.67 (a -54.65% decrease from previous year)
  • Annual EV/Sales for 2019 was 21.32 (a 168.98% increase from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Sales of Neovasc Inc.

Most recent EV/Salesof NVCN including historical data for past 10 years.

Interactive Chart of EV/Sales of Neovasc Inc.

Neovasc Inc. EV/Sales for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -0.98
2021 -4.17 1.15 3.72 -4.07 -4.17
2020 9.67 18.61 15.91 9.39 9.67
2019 21.32 16.85 15.62 8.23 21.32
2018 7.93 25.08 17.27 208.14 7.93
2017 9.65 18.48 11.51 11.39 9.65
2016 9.95 7.76 8.19 24.43 9.95
2015 25.05 25.75 33.05 37.65 25.05
2014 25.8 20.95 22.53 20.45 25.8
2013 15.39 10.67 13.33 13.61 15.39
2012 9.62 8.76 0.0 0.0 9.62
2011 0.0 0.0

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.